Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma

NCT00006013 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT00006013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2000
Completion date
January 31, 2003
Enrollment
21 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm